Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 1, 2015, Pages 9-13

  Blachly, James S ^a   Lozanski, Gerard ^a   Lucas, David M ^a   Grever, Michael R ^a   Kendra, Kari ^a   Andritsos, Leslie A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CD103 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CLADRIBINE; DABRAFENIB; GENOMIC DNA; GLYCOPROTEIN P 15095; HEMOGLOBIN; INTERLEUKIN 2 RECEPTOR ALPHA; PENTOSTATIN; SARGRAMOSTIM; SOLUBLE INTERLEUKIN 2 RECEPTOR; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; OXIME; PROTEIN KINASE INHIBITOR;

AGED; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SIZE; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTINUOUS INFUSION; COUGHING; DISEASE ACTIVITY; DISEASE DURATION; DRUG TOLERABILITY; DYSERYTHROPOIESIS; FATIGUE; GENE EXPRESSION; GENE MUTATION; HAIRY CELL LEUKEMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTOSIS; MALE; MELANOMA; MITOSIS RATE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR BIOPSY; WIDE EXCISION; ANTAGONISTS AND INHIBITORS; COMPUTER ASSISTED TOMOGRAPHY; GENETICS; LEUKEMIA, HAIRY CELL; MUTATION; POSITRON EMISSION TOMOGRAPHY; SECOND CANCER; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; HUMANS; IMIDAZOLES; LEUKEMIA, HAIRY CELL; MALE; MELANOMA; MUTATION; NEOPLASMS, SECOND PRIMARY; OXIMES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84921471023     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0004     Document Type: Article

References (16)

1. Kiel MJ, Velusamy T, Betz BL, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 2012;209:1553-1565.
2. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-6069.
3. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011;29:3574-3579.
4. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011;29:2046-2051.
5. Grisham RN, Iyer G, Garg K, et al. Braf mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013;119:548-554.
6. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-627.
7. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
8. Greaves WO, Verma S, Patel KP, et al. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn 2013;15:220-226.
9. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305-2315.
10. Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012;366:2038-2040.
11. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207-215.
12. Pakneshan S, Salajegheh A, Smith R, Lam A. Clinicopathological relevance of BRAF mutations in human cancer. Pathol 2013;45:346-356.
13. Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001;8:101-108.
14. Xi L, Arons E, Navarro W, et al. Both variant and ighv4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 2012;119:3330-3332.
15. Chung SS, Kim E, Park JH, et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med 2014;6:238ra71.
16. Champion KJ, Bunag C, Estep AL, et al. Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome. Clin Genet 2011;79:468-474.